8-K: TriSalus Reports Strong Q3 Revenue, Reaffirms 2025 Guidance

TriSalus Life Sciences announced robust third-quarter 2025 financial results, with revenue up 57% year-over-year, and reaffirmed its full-year revenue growth guidance of at least 50%.

Summary

• TriSalus Life Sciences reported $11.6 million in net sales for Q3 2025, marking a 57% increase year-over-year and 3% sequential growth over Q2 2025.
• The company reaffirmed its full-year 2025 revenue growth guidance of at least 50%, driven by strong commercial performance and increasing market penetration of its TriNav system.
• Quarterly cash burn was reduced by approximately 50% quarter-over-quarter.
• Gross margins for Q3 2025 were 84%, a slight decrease from 86% in Q3 2024, attributed to lower manufacturing efficiency for newly launched products.
• Operating losses increased slightly to $9.0 million in Q3 2025 from $8.7 million in Q3 2024, primarily due to a one-time charge of $2.1 million related to closing nelitolimod clinical studies and accelerated non-cash stock-based compensation.
• Net loss attributable to common stockholders was $41.3 million, significantly higher than $3.2 million in Q3 2024, mainly due to a $30.5 million impact from the conversion of preferred stock to common stock.
• Adjusted EBITDA losses improved to $5.4 million in Q3 2025 from $7.2 million in Q3 2024, reflecting increased sales and reduced R&D expenses (excluding the one-time charge).
• Cash and cash equivalents stood at $22.7 million as of September 30, 2025, providing sufficient runway to reach positive adjusted EBITDA.
• Completed PERIO clinical phase 1 dose escalation studies, with clinical study reports under preparation for data release in Q4.
• Initiated a clinical trial to evaluate genicular artery embolization (GAE) for knee osteoarthritis.

Sentiment

Score: 8

Explanation: The company demonstrated strong revenue growth, reaffirmed robust guidance, significantly reduced cash burn, and expanded its technology's applications. While net loss increased due to a non-operational preferred stock conversion, the underlying operational performance and strategic direction are highly positive, indicating strong momentum and a clear path to improved financial health.

Positives

• Revenue increased by 57% year-over-year to $11.6 million in Q3 2025, demonstrating strong commercial performance.
• Full-year 2025 revenue growth guidance of at least 50% was reaffirmed, indicating continued confidence in market penetration.
• Quarterly cash burn was significantly lowered by approximately 50% quarter-over-quarter.
• Adjusted EBITDA losses improved to $5.4 million from $7.2 million in the prior year, reflecting operational efficiencies and sales growth.
• Successful completion of an exchange offering simplified the company's capital structure.
• Investigator-published data showed the TriNav Infusion System enables safe and effective thyroid artery embolization, expanding potential applications.
• Initiated a new clinical trial for genicular artery embolization (GAE) as a potential treatment for knee osteoarthritis, broadening the PEDD platform's reach.
• Cash and cash equivalents of $22.7 million provide sufficient runway to reach positive adjusted EBITDA.

Negatives

• Gross margins slightly declined to 84% in Q3 2025 from 86% in Q3 2024, primarily due to lower manufacturing efficiency for newly launched products.
• Operating losses increased to $9.0 million from $8.7 million year-over-year, impacted by one-time charges.
• Net loss attributable to common stockholders significantly widened to $41.3 million from $3.2 million, largely due to a $30.5 million non-cash impact from preferred stock conversion.
• Basic and diluted loss per share increased to $0.96 from $0.12, also primarily due to the preferred stock conversion.

Risks

• Risks associated with clinical development and regulatory approval of drug delivery and pharmaceutical product candidates.
• Future clinical results may not be consistent with patient data generated during prior clinical trials.
• Uncertainty regarding the cost and timing of all development activities and clinical trials.
• Potential for unexpected safety and efficacy data observed during clinical studies.
• Risks associated with the credit facility, including the company's ability to remain in compliance with all obligations to avoid an event of default.
• The risk that the company will continue to raise capital through the issuance and sale of its equity securities to fund operations.
• The risk that the company will not be able to achieve the applicable revenue requirements to access additional financing under the credit facility.
• The risk that the company will not become profitable on its expected timeline, if at all.
• The risk that reported financial results will differ from estimates provided.
• Changes in expected or existing competition or market conditions.
• Changes in the regulatory environment.
• Potential for unexpected litigation or other disputes.
• Unexpected expensed costs.

Future Outlook

The company reaffirmed its full-year 2025 revenue growth guidance of at least 50%, driven by continued commercial momentum for TriNav. It expects gross margins to improve as production scales and processes mature. TriSalus is committed to expanding its PEDD technology platform to new embolization applications and is exploring partnership opportunities for the development of its investigational immunotherapeutic, nelitolimod. The current cash position of $22.7 million is deemed sufficient to reach positive adjusted EBITDA.

Management Comments

• "TriSalus continued to deliver strong commercial performance in the third quarter, underscoring the growing clinical adoption of our TriNav product suite and proprietary PEDD platform across a broad range of solid tumor indications."
• "We are pleased to reaffirm our full-year revenue growth guidance of 50%, reflecting the increasing market penetration of TriNav for liver-directed therapies."
• "We continue to invest in registry and other clinical programs and are committed to building a data-driven case for the expansion of our PEDD technology platform to new embolization applications."
• "With our strategic shift toward partnering development of nelitolimod, we are also reducing our quarterly cash burn even as we extend our platform."
• "We look forward to the balance of 2025 energized by our long-term vision of bringing our PEDD technology to a wider range of patients and improving their clinical outcomes."

Industry Context

TriSalus operates in the oncology medical technology sector, focusing on innovative drug delivery systems and investigational immunotherapies for solid tumors. Its PEDD platform and TriNav system are positioned to enhance the delivery of standard-of-care therapies, with expanding applications beyond liver-directed treatments to areas like thyroid and potentially knee osteoarthritis. The strategic shift to partner nelitolimod development reflects a common industry approach to de-risk and accelerate drug development while focusing internal resources on core technology platforms.

Comparison to Industry Standards

• The filing does not provide specific comparisons to comparable companies, projects, or results within the industry. The focus is on the company's internal growth metrics and clinical advancements of its proprietary PEDD technology and TriNav system.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact from strong revenue growth, reaffirmed guidance, and reduced cash burn. However, the significant increase in net loss attributable to common stockholders due to preferred stock conversion may cause short-term concern regarding EPS.
• Patients: Potential positive impact through the expansion of the PEDD technology to new applications (e.g., thyroid embolization, knee osteoarthritis) and continued development of immunotherapeutic candidates.
• Employees: Continued growth and strategic initiatives may offer stability and opportunities, though the strategic shift for nelitolimod development could imply resource reallocation.
• Creditors: Improved cash burn and a stated runway to positive adjusted EBITDA suggest a stronger financial position to meet obligations.

Next Steps

• Release of clinical study reports for PERIO phase 1 dose escalation studies in Q4 2025.
• Continued investment in registry and other clinical programs to build a data-driven case for PEDD technology expansion.
• Exploring partnership opportunities for the development of nelitolimod.
• Hosting a conference call and webcast on November 13, 2025, to discuss financial results and operational updates.

Key Dates

Recommendation

The company exhibits strong operational momentum with 57% year-over-year revenue growth and reaffirmed robust full-year guidance. A significant reduction in cash burn and improved Adjusted EBITDA losses demonstrate effective financial management. While the reported net loss is substantial, it is primarily an accounting artifact of preferred stock conversion, not an operational deterioration. The expansion of the PEDD platform into new clinical applications (thyroid, knee osteoarthritis) broadens market potential, and the strategic partnering of nelitolimod development is a prudent move to optimize resources. These factors collectively point to a positive trajectory and undervaluation relative to future growth prospects.

Keywords

Oncology, Medical Technology, Drug Delivery, TriNav, PEDD Platform, Liver Embolization, Thyroid Embolization, Knee Osteoarthritis, Immunotherapy, Nelitolimod, Financial Results, Revenue Growth, Cash Burn, Biotechnology